FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Thinking, Hands, and MS!


















































ECTRIMS 2016 (European Committee for Treatment and Research in MS) produced lots of stories with exciting headlines about advances in MS research — and hopefully you read many of them here at MS News Today. As I went through the various presentation titles, there were a couple that jumped out at me, made me pause, and even made me smile a bit. They both involved a combination of thinking, hands, and MS.

First was a study that challenges the EDSS (Expanded Disability Severity Scale) as the gold standard for measuring the success of a drug undergoing a trial.

From the abstract titled “Multiple sclerosis, EDSS, and objective cognitive function: a walking scale with no apparent brains and limited thought,” the authors note: “EDSS is universally accepted to measure treatment efficacy but cognitive function does not impact EDSS. Cognitive function varies independently of walking ability and is an important aspect of PwMS (people with MS) disease impact.”

From their study of 258 people with MS they came to the conclusion: “EDSS is insensitive to assess individual PwMS cognitive ability and does not predict accumulated cognitive disability. Cognitive impairment in PwMS, independently of EDSS, correlates with many important milestones. EDSS use as a solitary gold standard in measuring unique accumulated PwMS disability should be reconsidered.”

The authors appear to present the finding that there should be more to look at for outcomes in people involved in a clinical trial than just how fast they can walk, or whether they need an assistive device (cane, walker, wheelchair) to safely move around. I look forward to reading more on the study when results become available, but for now I can only see the abstract under a provocative title.

Second, the idea that there should be other trial measurements in addition to whether we can walk, was also a larger part of ECTRIMS, as one of their “burning debate” conversations.

In fact, #ThinkHand was introduced by the group from Neuroimmunology, Blizard Institute, Barts and The London School of Medicine and Dentistry — and they carried on this conversation throughout ECTRIMS 2016.

Their argument shared the view that even though people may be in wheelchairs, they should still be part of trials for progressive MS treatments because upper limb function and cognitive function are more important to most people with MS than their ability to walk. I believe we should include hand function as part of study outcomes, but presently that is not the case because almost all trials have improvement in the EDSS as one of their endpoints.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News